| 前收市價 | 1.2800 |
| 開市 | 1.2800 |
| 買盤 | 1.2700 x 100 |
| 賣出價 | 1.2900 x 100 |
| 今日波幅 | 1.2500 - 1.3354 |
| 52 週波幅 | 0.6500 - 2.1200 |
| 成交量 | |
| 平均成交量 | 382,568 |
| 市值 | 96.134M |
| Beta 值 (5 年，每月) | 2.33 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.5300 |
| 業績公佈日 | 2024年5月09日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 5.50 |
Insider MonkeyClearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript March 13, 2024 Clearside Biomedical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Clearside Biomedical Q4 2023 Financial Results and Corporate Update Call. At this […]
InvestorPlace7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum. This is a good time to remind you of all the reasons you shouldn’t buy biotech penny stocks. The first reason centers on the last two words. While many of these companies may claim advanced clinical data and whatnot, the reality is that many if not most players in this field wil
- Insider Monkey
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript November 13, 2023 Clearside Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.16. Operator: Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode and a question-and-answer […]
